Better Health for All

Dermata Therapeutics is a clinical-stage biotechnology company entirely focused on developing innovative treatments for medical and aesthetic skin conditions such as acne, psoriasis, and hyperhidrosis

. These conditions affect millions globally and negatively impact quality of life and emotional well-being, including causing lowered self-esteem and social withdrawal, which the company aims to alleviate . Its lead product candidate, XYNGARI™ (DMT310), a once-weekly topical treatment for moderate-to-severe acne, met all primary endpoints in its Phase 3 STAR-1 trial , demonstrating statistically significant improvements (29.4% IGA success vs 15.2% placebo) . The company is pivoting to over-the-counter (OTC) products, starting with an acne kit , to enhance accessibility , though it also aims for favorable pricing and believes patients will pay higher out-of-pocket costs . Products consistently show good safety and tolerability in trials, with minimal treatment-related adverse events and no serious adverse events reported , and traditional use of its Spongilla technology by over one million people annually in Russia reported few safety issues . Clinical trials are conducted ethically, adhering to randomized, double-blind, placebo-controlled designs , with independent institutional review board (IRB) oversight , good clinical practice (GCP), and public disclosure on clinicaltrials.gov . Trials enroll diverse populations, including patients aged 9 years and older in the U.S. and Latin America . The company adheres to standard regulatory disclosures for risks in its annual reports and clinical trial data . The company's focus is overwhelmingly on treatment, with minimal emphasis on preventative health measures.

Fair Money & Economic Opportunity

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on research, development, and clinical trials, not a financial institution.

The value 'Fair Money & Economic Opportunity' and its associated KPIs are designed to assess financial institutions. As such, the company does not offer lending, deposit, or other financial services to consumers. No evidence was found in the provided articles that directly addresses any of the KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, customer data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, or product simplicity.

Fair Pay & Worker Respect

Dermata Therapeutics, Inc. has no regulatory actions, violations, fines, or compliance issues mentioned in the provided article.

Information to assess other KPIs, such as living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, and health insurance coverage, is not available. While executive compensation figures are provided, median employee compensation is not, preventing the calculation of the CEO-to-median pay ratio.

No War, No Weapons

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on medical dermatology products. The company's core business is not involved in defense or arms-related activities. The provided articles explicitly state that KPIs related to arms contracts, dual-use technology, sales to embargoed regimes, conflict divestment, board oversight of defense, export certifications, defense lobbying, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, dual-use screening, surveillance, ethical red lines for weapons, exposure to controversial weapons, war-risk audits, conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, and ethical red lines compliance are 'Not applicable' to a pharmaceutical company.

No evidence was found for peacebuilding investment, procurement humanitarian compliance, or UN Guiding Principles alignment.

Planet-Friendly Business

Dermata Therapeutics, Inc. has a low SDG Transparency Score of 0, last updated on May 1, 2024.

The company's Spongilla technology uses a naturally grown freshwater sponge, Spongilla lacustris, which grows in select regions and can regenerate annually. The company has an exclusive supply agreement for this raw material with a Russian entity and acknowledges that sanctions and export controls related to Russia could impact its ability to obtain the material. Proprietary harvesting protocols have been developed with its exclusive supplier, who has over 22 years of experience and recognizes necessary environmental conditions for optimal raw material harvest. Dermata Therapeutics relies on third-party and foreign suppliers for its raw materials.

Respect for Cultures & Communities

No evidence was found in the provided articles to assess Dermata Therapeutics, Inc. against the 'Respect for Cultures & Communities' ethical value. The articles focus on the company's biotechnology business model, product development, clinical trial results

, and job postings , without providing specific data points related to community engagement, cultural impact, local employment, or any other relevant metrics for this value.

Safe & Smart Tech

The company regularly provides all employees with a data protection, cybersecurity, incident response, and prevention training and compliance program.

Its primary means of minimizing cybersecurity risk is by limiting the amount of sensitive data within its enterprise through fully outsourcing its IT environment to expert third-party software-as-a-service, human resource, and clinical providers. The company has processes for assessing, identifying, and managing cybersecurity risks, which include physical, procedural, and technical safeguards, response plans, and tests on its systems. The company is subject to regulation by federal and state governments, including the FDA, and states that failure to comply with applicable requirements may lead to sanctions. The Audit Committee of the Board provides direct oversight over cybersecurity risk and provides updates to the Board periodically.

Zero Waste & Sustainable Products

The company's third-party suppliers and manufacturers engage in the controlled storage, use, and disposal of hazardous materials, including components of product candidates.

There is no specific information regarding waste diversion, product or packaging recyclability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, product durability, repairability, waste audits, zero waste certifications, waste disposal violations, material efficiency, packaging ratios, waste reduction targets, supplier waste requirements, or customer waste education. The company is also working on branding and packaging for an OTC product line planned for launch in mid-2026, but no sustainability metrics for this are provided.